
EquitySector - HealthcareVery High Risk
Direct
NAV (12-Feb-26)
Returns (Since Inception)
Fund Size
₹6,658 Cr
Expense Ratio
1.02%
ISIN
INF109KC1GH2
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+7.09%
+6.41% (Cat Avg.)
3 Years
+27.69%
+23.11% (Cat Avg.)
5 Years
+17.77%
+14.87% (Cat Avg.)
Since Inception
+20.63%
— (Cat Avg.)
| Equity | ₹6,498.51 Cr | 97.60% |
| Others | ₹159.9 Cr | 2.40% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹745.57 Cr | 11.20% |
| Cipla Ltd | Equity | ₹627.97 Cr | 9.43% |
| Dr Reddy's Laboratories Ltd | Equity | ₹483.96 Cr | 7.27% |
| Mankind Pharma Ltd | Equity | ₹421.98 Cr | 6.34% |
| Divi's Laboratories Ltd | Equity | ₹414.3 Cr | 6.22% |
| Biocon Ltd | Equity | ₹389.71 Cr | 5.85% |
| Lupin Ltd | Equity | ₹319.57 Cr | 4.80% |
| Aurobindo Pharma Ltd | Equity | ₹260.34 Cr | 3.91% |
| Syngene International Ltd | Equity | ₹199.11 Cr | 2.99% |
| Alkem Laboratories Ltd | Equity | ₹193.01 Cr | 2.90% |
| Cohance Lifesciences Ltd | Equity | ₹186.43 Cr | 2.80% |
| Treps | Cash - Repurchase Agreement | ₹164.84 Cr | 2.48% |
| Zydus Lifesciences Ltd | Equity | ₹155.92 Cr | 2.34% |
| Alivus Life Sciences Ltd | Equity | ₹151.53 Cr | 2.28% |
| Alembic Pharmaceuticals Ltd | Equity | ₹119.29 Cr | 1.79% |
| Thyrocare Technologies Ltd | Equity | ₹117.79 Cr | 1.77% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹108.44 Cr | 1.63% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹108.19 Cr | 1.62% |
| Entero Healthcare Solutions Ltd | Equity | ₹106.23 Cr | 1.60% |
| Gland Pharma Ltd | Equity | ₹106.16 Cr | 1.59% |
| Medplus Health Services Ltd | Equity | ₹96.37 Cr | 1.45% |
| Medi Assist Healthcare Services Ltd | Equity | ₹96.02 Cr | 1.44% |
| Pfizer Ltd | Equity | ₹82.59 Cr | 1.24% |
| Metropolis Healthcare Ltd | Equity | ₹82.07 Cr | 1.23% |
| Blue Jet Healthcare Ltd | Equity | ₹77.24 Cr | 1.16% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹76.37 Cr | 1.15% |
| Hikal Ltd | Equity | ₹76.28 Cr | 1.15% |
| Windlas Biotech Ltd | Equity | ₹72.81 Cr | 1.09% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹72.31 Cr | 1.09% |
| Aarti Drugs Ltd | Equity | ₹69.51 Cr | 1.04% |
| Anthem Biosciences Ltd | Equity | ₹63.08 Cr | 0.95% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹56.71 Cr | 0.85% |
| Shilpa Medicare Ltd | Equity | ₹56.62 Cr | 0.85% |
| Senores Pharmaceuticals Ltd | Equity | ₹50.5 Cr | 0.76% |
| AstraZeneca Pharma India Ltd | Equity | ₹49.83 Cr | 0.75% |
| Rubicon Research Ltd | Equity | ₹49.38 Cr | 0.74% |
| FDC Ltd | Equity | ₹45.24 Cr | 0.68% |
| Laxmi Dental Ltd | Equity | ₹41.73 Cr | 0.63% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹30.43 Cr | 0.46% |
| Nephrocare Health Services Ltd | Equity | ₹29.02 Cr | 0.44% |
| Procter & Gamble Health Ltd | Equity | ₹8.9 Cr | 0.13% |
| Net Current Assets | Cash | ₹-7.32 Cr | 0.11% |
| 09/04/2026 Maturing 91 DTB | Bond - Gov't/Treasury | ₹1.98 Cr | 0.03% |
| Cash Margin - Derivatives | Cash - Collateral | ₹0.41 Cr | 0.01% |
Large Cap Stocks
34.12%
Mid Cap Stocks
28.23%
Small Cap Stocks
35.24%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹6,426.2 Cr | 96.51% |
| Basic Materials | ₹72.31 Cr | 1.09% |
Standard Deviation
This fund
16.02%
Cat. avg.
16.18%
Lower the better
Sharpe Ratio
This fund
1.19
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.60
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GH2 | Expense Ratio 1.02% | Exit Load 1.00% | Fund Size ₹6,658 Cr | Age 7 years 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹11,50,127 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments